Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results